Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial.

MLA

Krystal, John H., et al. “Emraclidine, a Novel Positive Allosteric Modulator of Cholinergic M4 Receptors, for the Treatment of Schizophrenia: A Two-Part, Randomised, Double-Blind, Placebo-Controlled, Phase 1b Trial.” Lancet (London, England), vol. 400, no. 10369, Dec. 2022, pp. 2210–20. EBSCOhost, https://doi.org/10.1016/S0140-6736(22)01990-0.

APA

Krystal, J. H., Kane, J. M., Correll, C. U., Walling, D. P., Leoni, M., Duvvuri, S., Patel, S., Chang, I., Iredale, P., Frohlich, L., Versavel, S., Perry, P., Sanchez, R., & Renger, J. (2022). Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. Lancet (London, England), 400(10369), 2210–2220. https://doi.org/10.1016/S0140-6736(22)01990-0

Chicago

Krystal, John H, John M Kane, Christoph U Correll, David P Walling, Matthew Leoni, Sridhar Duvvuri, Shrinal Patel, et al. 2022. “Emraclidine, a Novel Positive Allosteric Modulator of Cholinergic M4 Receptors, for the Treatment of Schizophrenia: A Two-Part, Randomised, Double-Blind, Placebo-Controlled, Phase 1b Trial.” Lancet (London, England) 400 (10369): 2210–20. doi:10.1016/S0140-6736(22)01990-0.